S. Korea's Boryung Seeks Approval To Market Chinese H1N1 Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
Boryung Pharmaceutical of South Korea applied to the government for marketing approval for the H1N1 flu vaccine developed by China's Sinovac Biotech